Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The US Congress authorized the Patient-Centered Outcomes Research Institute (PCORI) in 2010 to fund comparative clinical effectiveness research (CER) “to assist patients, clinicians, purchasers, and policy-makers in making informed health decisions.”1 This charge is unique. No other health research funding agency is restricted to funding CER, defined as “comparing health outcomes and the clinical effectiveness, risks, and benefits of 2 or more medical treatments, services….”1 No other funding agency must address the research needs of the entire range of stakeholders in the health care enterprise. To respond to these mandates, PCORI’s board of governors, methodology committee, and staff have built a novel “stakeholder-driven” approach to doing CER. The premise: research is more likely to improve the care of patients if they and other key stakeholders are involved in all aspects of the research.
Selby JV, Forsythe L, Sox HC. Stakeholder-Driven Comparative Effectiveness ResearchAn Update From PCORI. JAMA. 2015;314(21):2235-2236. doi:10.1001/jama.2015.15139